Diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes who use automated insulin delivery systems.

Type 1 diabetes (T1D) is an autoimmune condition where the immune system destroys insulin-producing β-cells in the pancreas. Yet, not all patients lose insulin function at the same pace. Understanding this variation is especially important in Japanese populations, who tend to experience faster and more complete loss of insulin secretion than their Western counterparts.

Canada can learn from England’s successful diabetes prevention program to build its own programs to tackle diabetes prevention across the country, argue the authors in an analysis in the Canadian Medical Association Journal.

Diabetic foot ulcers (DFUs) are a major clinical challenge, with high rates of morbidity, disability, amputations and mortality. Despite extensive research, effective predictive biomarkers for DFUs healing remain elusive.

Western Sydney University researchers have led a global team to pioneer a new AI-powered tool to assess the risk of developing type 1 diabetes (T1D) and predict treatment responses, potentially changing how the disease is diagnosed and managed.

In a new study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nutrients, waste and water in and out of the retina.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i), or gliflozins, are medications used in the treatment of type 2 diabetes mellitus (T2DM). They are designed to lower high blood glucose levels typical in T2DM, and work by inhibiting the sodium-glucose transport protein 2. SGLT2i have also been shown to improve outcomes among patients with chronic kidney disease, heart failure and coronary artery disease.

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online April 22 in the Annals of Internal Medicine.

More than 2.5 billion adults worldwide are overweight or obese. Many develop type 2 diabetes (T2D) and other complications. Bariatric surgery is an effective treatment option for significantly reducing weight and reducing the risk of complications. However, it is still difficult to predict the benefits of bariatric surgery for people without T2D.

The highs and lows of blood glucose aren’t just an energy rollercoaster; they could be a key to detecting diabetes risk early and spare you a needle prick or two.